These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27602492)

  • 1. Anti-hepatocellular carcinoma properties of the anti-alcoholism drug disulfiram discovered to enzymatically inhibit the AMPK-related kinase SNARK in vitro.
    Goto K; Kato N; Chung RT
    Oncotarget; 2016 Nov; 7(46):74987-74999. PubMed ID: 27602492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling.
    Goto K; Lin W; Zhang L; Jilg N; Shao RX; Schaefer EA; Zhao H; Fusco DN; Peng LF; Kato N; Chung RT
    J Hepatol; 2013 Nov; 59(5):942-8. PubMed ID: 23831117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
    Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
    J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction of disulfiram and H
    Read E; Milford J; Zhu J; Wu L; Bilodeau M; Yang G
    Toxicol Appl Pharmacol; 2021 Sep; 426():115642. PubMed ID: 34242567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
    Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
    Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners.
    Chiba T; Suzuki E; Yuki K; Zen Y; Oshima M; Miyagi S; Saraya A; Koide S; Motoyama T; Ogasawara S; Ooka Y; Tawada A; Nakatsura T; Hayashi T; Yamashita T; Kaneko S; Miyazaki M; Iwama A; Yokosuka O
    PLoS One; 2014; 9(1):e84807. PubMed ID: 24454751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway.
    Wang Y; Wu J; Lin B; Li X; Zhang H; Ding H; Chen X; Lan L; Luo H
    Toxicology; 2014 Dec; 326():9-17. PubMed ID: 25268046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
    Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
    Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
    Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
    Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways.
    Xu Y; Zhou Q; Feng X; Dai Y; Jiang Y; Jiang W; Liu X; Xing X; Wang Y; Ni Y; Zheng C
    Biomed Pharmacother; 2020 Jun; 126():110048. PubMed ID: 32145587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line.
    Hoda M; Pajaniradje S; Shakya G; Mohankumar K; Rajagopalan R
    Nanomedicine; 2016 Aug; 12(6):1641-50. PubMed ID: 27013133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.
    Ren X; Li Y; Zhou Y; Hu W; Yang C; Jing Q; Zhou C; Wang X; Hu J; Wang L; Yang J; Wang H; Xu H; Li H; Tong X; Wang Y; Du J
    Redox Biol; 2021 Oct; 46():102122. PubMed ID: 34482117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
    Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
    Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
    Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
    Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics.
    Wu Q; Zhang M; Wen Y; He P; He Q; Yang B; Jiang L; Yuan M; Cao J
    Eur J Pharmacol; 2022 Jul; 926():175035. PubMed ID: 35605658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein phosphatase 5 promotes hepatocarcinogenesis through interaction with AMP-activated protein kinase.
    Chen YL; Hung MH; Chu PY; Chao TI; Tsai MH; Chen LJ; Hsiao YJ; Shih CT; Hsieh FS; Chen KF
    Biochem Pharmacol; 2017 Aug; 138():49-60. PubMed ID: 28528695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
    Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP
    Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel.
    Xu X; Xu J; Zhao C; Hou X; Li M; Wang L; Chen L; Chen Y; Zhu L; Yang H
    Biomed Pharmacother; 2019 Dec; 120():109529. PubMed ID: 31606620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.